HomeAI · summaries
Storia in 2 fonti
Gilead, Merck’s phase 3 data back first weekly HIV pill
Detailed phase 3 results suggest the two-drug combination of Gilead Sciences’ lenacapavir and Merck & Co.’s islatravir has what it takes to become the first complete weekly pill for the treatme | Detailed phase 3 results from two Islend clinical trials confirmed that a once-weekly, single-tablet combination of Merck’s islatravir and Gilead’s lenacapavir matches daily treatments like Biktarvy at maintaining HIV viral suppression
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
fiercepharma.com
Gilead, Merck’s phase 3 data back first weekly HIV pill
Detailed phase 3 results suggest the two-drug combination of Gilead Sciences’ lenacapavir and Merck & Co.’s islatravir has what it takes to become the first complete weekly pill…
- ·
benzinga.com
Gilead, Merck Advance Potential Blockbuster Weekly HIV Pill - Merck & Co (NYSE:MRK), Gilead Sciences (NAS
Gilead & Merck Phase 3 data shows once-weekly ISL/LEN matches daily HIV meds in viral suppression through 48 weeks.